Concepedia

Author

Annie Luetkemeyer

University of California, San Francisco

Also Known As

A Luetkemeyer, A. F. Luetkemeyer, A. Luetkemeyer, Annie F. Luetkemeyer, Annie Luetkemeyer, Gary Luckasen, Gregg H. Lucksinger, Landovitz, Raphael, Margaret Green, Marshall Glesby

46

Publications

8.7K

Citations

19

H-Index

14

Concepts

All Affiliations

University of California, San FranciscoSan Francisco General HospitalUniversity of Colorado DenverCancer Research And BiostatisticsNational Institute of Allergy and Infectious Diseases
AL

About

Annie Luetkemeyer is an author at University of California, San Francisco specializing in medicine, virology, and hepatitis.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

109

2

Immunology

2

2

49

3

Epidemiology

1

1

24

4

Hepatology

1

1

24

5

Pharmacology

1

1

30

Annie Luetkemeyer

×

16

Publications

8.3K

Citations

15

H-Index

YearCitations

Remdesivir for the Treatment of Covid-19 — Final Report

John H. Beigel, Kay M Tomashek, Lori E. Dodd,

New England Journal of Medicine

2020

7.6K

Comparison of an Interferon-γ Release Assay with Tuberculin Skin Testing in HIV-infected Individuals

Annie Luetkemeyer, Edwin D. Charlebois, Laura Flores,

American Journal of Respiratory and Critical Care Medicine

2007

203

Clinical Presentation and Course of Acute Hepatitis C Infection in HIV-Infected Patients

Annie Luetkemeyer, C. Bradley Hare, John Stansell,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2005

121

Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata.

Gabriel Chamie, Annie Luetkemeyer, Maria Walusimbi-Nanteza,

PubMed

2010

75

Tuberculosis Biomarker and Surrogate Endpoint Research Roadmap

Payam Nahid, Jussi Saukkonen, William R. Mac Kenzie,

American Journal of Respiratory and Critical Care Medicine

2011

60

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study

David Wyles, Norbert Bräu, S. Kottilil,

Journal of Hepatology

2016

36

Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations

Meghan D. Morris, Claire McDonell, Annie Luetkemeyer,

JAMA Network Open

2023

31

Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-based Antituberculosis Therapy in the STRIDE Study

Annie Luetkemeyer, S. Rosenkranz, Darlene Lu,

Clinical Infectious Diseases

2015

30

Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals

Susanna Naggie, Daniel S. Fierer, Michael D. Hughes,

Clinical Infectious Diseases

2018

27

A pilot metabolomics study of tuberculosis immune reconstitution inflammatory syndrome

Carlos A. M. Silva, Barbara Graham, Kristofor J. Webb,

International Journal of Infectious Diseases

2019

26

Page 1